Skip to content

Cervical pessary for the prevention of preterm delivery.

Cervical pessary for the prevention of preterm delivery. - Preterm LabOr preVEntion, Multicenter study fOr Maternal cervical pessary(LOVE MOM)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025404
Enrollment
100
Registered
2017-01-15
Start date
2017-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Delivery

Interventions

Cervical pessary from 20weeks to 36weeks gestation.

Sponsors

Department of Obstetrics and Gynecology Nagoya City University, Graduate School of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Pregnant women after 20 weeks gestation, who is disgnosed threatened miscarriage or threatened premature labor. 2)Cervical length of 25mm or less. 3)Women with informed consent for participation in this trial.

Exclusion criteria

Exclusion criteria: 1)Women with multiple pregnant. 2)Majior fetal anomalies. 3)Painful regular uterine contractions. 4)Active vaginal bleeding. 5)Placenta previa. 6)Cervical myoma. 7)History of cone biopsy or cervical cerclage in situ. 8)Other pregnant women when study doctores conclude that they are not eligible for study enrollment.

Design outcomes

Primary

MeasureTime frame
Delivery less than 34 weeks gestation.

Secondary

MeasureTime frame
A)Efficacy Delivery less than 37weeks, Delivery less than 28weeks, Rupture of membrane less than 34 weeks B)maternal background age, pregnancy history, previous medical history, hight, body weight, smoking C)Safty Way of delivery, Bleeding at delivery, Cevical laceration, Uterus rupture, pessaty withdrawal, Chorioamnionitis, Vaginitis D)Treatment for mother Cervical length, corticosteroid treatment for fetal maturation E)Background for baby body weight, Gestational weeks at birth, Apgar score, Evaluation fo umbilical arterial blood gas F)Safty for baby Fetal death, Neonatal death, Adverse outcomes(Intraventricular hemorrhage, Respiratory distress syndrome, Retinopathy, Necrotising enterocolitis, Sepsis) G)Treatment for baby Respiratory treatment, Photo therapy, Antibiotics, Blood transfurion

Countries

Japan

Contacts

Public ContactKyoko KUMAGAI

Nagoya City University Hostpital Department of Obstetrics and Gynecology

og-nzw@med.nagoya-cu.ac.jp052-851-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026